M&A · Healthcare · Pharmaceutical Preparations
Pathos AI, Inc. to acquire Rain Oncology Inc.
Announced Dec 13, 2023 · Closed Jan 26, 2024
Deal value$42MEV $5M
Premium17.0%To unaffected price
EV / Adj. EBITDA—
ConsiderationAll cash$1.16 per share
Transaction
- Acquirer
- Pathos AI, Inc.
- Target
- Rain Oncology Inc. (RAIN)
- Buyer type
- Strategic
- Offer price per share
- $1.16
- Enterprise value
- $5M
- Status
- Closed Jan 26, 2024
Deal protections
- Break fee (target pays)
- $1.5M · 3.6%
- Reverse fee (buyer pays)
- —
- Go-shop
- —
- Financing
- No financing condition
Advisors
- To the acquirer
- Not disclosed
- To the target
- Leerink Partners
Sector context · Healthcare
- Comparable deals
- 99 in the prior 24 months
- Premium
- 17.0% vs. 52.0% sector median
- EV / Adj. EBITDA
- Sector median 17.1x
- Break fee
- 3.6% vs. 3.5% sector median
Timeline
- AnnouncedDec 13, 2023
- Tender offerDec 14, 2023
- ClosedJan 26, 2024